<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱

Amuvatinib - MP 470

產(chǎn)品貨號(hào)

Axon 2368 CAS [850879-09-3] MF C23H21N5O3SMW 447.51 Purity: 99% Soluble in DMSO Description RTK inhibitor which effectively inhibits PDGFR, c-Kit and c-Met (IC50 values low μM range in vivo). Amuvatinib influences various survival and DNA repair related proteins such as pAKT, RAD51 and GSK-3β, inhibits cell proliferation, induces cell growth arrest and promotes apoptosis in prostate LNCaP cancer cells with?low μM IC50 values. When combined with Erlotinib (Axon 1128), Amuvatinib?abolished HER family/PI3K/Akt pathway with associated tumor growth inhibition in prostate cancer. References Certificates Categories Extra info W. Qi et al. MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer. BMC Cancer. 2009, 9, 142. ? D. Mahadevan et al. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene. 2007, , 26, 3909-3919.? ? C.J. Phillip et al. Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines. J. Hematol. Oncol. 2013, 6, 1-16. ? J.W. Welsh et al. The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. Radiat. Oncol. 2009, 4, 69. Certificate of Analysis Material Safety Data Sheet Angiogenesis Apoptosis Cell Cycle Regulation Cell Signaling & Oncology BCR-ABL c-MET FLT3 PDGFR PI3K-Akt-mTOR c-KIT RTK class III; EC 2.7.10.1 RTK inhibitor which effectively inhibits PDGFR, c-Kit and c-Met Chemical name N-(Benzo[d][1,3]dioxol-5-ylmethyl)-4-(benzofuro[3,2-d]pyrimidin-4-yl)piperazine-1-carbothioamide Parent CAS No. [850879-09-3] Order Size Unit Price Stock 10 mg €105.00 In Stock

產(chǎn)品價(jià)格

現(xiàn)貨詢價(jià)，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

Amuvatinib - MP 470

Based on 16 reference(s) in Google Scholar 9 10 16

Axon 2368

CAS [850879-09-3]

MF C23H21N5O3S
MW 447.51

Purity: 99%
Soluble in DMSO

Amuvatinib

Description

RTK inhibitor which effectively inhibits PDGFR, c-Kit and c-Met (IC50 values low μM range in vivo). Amuvatinib influences various survival and DNA repair related proteins such as pAKT, RAD51 and GSK-3β, inhibits cell proliferation, induces cell growth arrest and promotes apoptosis in prostate LNCaP cancer cells with?low μM IC50 values. When combined with Erlotinib (Axon 1128), Amuvatinib?abolished HER family/PI3K/Akt pathway with associated tumor growth inhibition in prostate cancer.

W. Qi et al. MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer. BMC Cancer. 2009, 9, 142.

D. Mahadevan et al. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene. 2007, , 26, 3909-3919.?

C.J. Phillip et al. Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines. J. Hematol. Oncol. 2013, 6, 1-16.

J.W. Welsh et al. The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. Radiat. Oncol. 2009, 4, 69.

Certificate of Analysis
Material Safety Data Sheet

Angiogenesis Apoptosis Cell Cycle Regulation Cell Signaling & Oncology BCR-ABL c-MET FLT3 PDGFR PI3K-Akt-mTOR c-KIT RTK class III; EC 2.7.10.1

RTK inhibitor which effectively inhibits PDGFR, c-Kit and c-Met

Chemical name

N-(Benzo[d][1,3]dioxol-5-ylmethyl)-4-(benzofuro[3,2-d]pyrimidin-4-yl)piperazine-1-carbothioamide

Parent CAS No.

[850879-09-3]

產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>